CAR-T Cell Therapy: Products, Evidence, Risks and Access
Author and compiler: Reza Abdollahi · Content type: Treatment evidence and access overview · Last updated: 2026-11-11
CAR-T is a family of engineered T-cell treatments—not one interchangeable therapy. The product, target, cancer subtype, previous treatment and jurisdiction all matter. This page explains the treatment process, selected regulatory examples and safety questions. It does not assess individual eligibility, interpret records or arrange treatment. Country-specific access, cost and hospital details are on each destination page, not here.
Quick Answer
CAR-T cells are engineered to recognise a selected target on cells. In the autologous products discussed here, T cells are collected from the patient, modified and manufactured, then infused after a product-specific preparation regimen. CAR-T has approved uses in selected blood cancers. There are also jurisdiction-specific developments in solid tumours: an NMPA announcement in June 2026 reported approval of a CLDN18.2-directed product for a defined gastric/GEJ cancer indication. This does not make CAR-T an established treatment for all solid tumours. Serious risks include CRS, neurological toxicity, infection, prolonged low blood counts and other product-specific complications. Some patients require intensive care; not every patient or every adverse event does. Eligibility and treatment planning belong to the responsible clinical team under the product label or research protocol, with the patient's informed participation.
How autologous CAR-T works
In autologous CAR-T, the patient's T cells are collected through leukapheresis. They are genetically modified to express a chimeric antigen receptor, expanded and tested before release. The receptor recognises a chosen target; a CAR-T product cannot be assumed to recognise every cancer. The sequence involves more than the infusion:
| Stage | What to clarify |
|---|---|
| Assessment | Diagnosis, previous therapy, current disease status and fitness for the proposed product. |
| Collection | Date, collection requirements and what could prevent an adequate collection. |
| Manufacturing and release | Expected timing, release requirements and what happens if manufacturing is delayed or unsuccessful. |
| Bridging treatment, if needed | Whether disease-control treatment is needed while waiting. |
| Reassessment | Whether the patient remains ready to proceed. |
| Lymphodepletion | The preparation regimen and its risks. |
| Infusion and early monitoring | Inpatient or outpatient plan, emergency support and caregiver requirements. |
| Longer-term follow-up | Response assessment, blood-count recovery, infection risk and late effects. |
Collection, manufacturing, bridging and monitoring do not have one universal timetable. Ask the centre for the schedule applicable to the exact product and for contingencies if the disease or manufacturing timeline changes. For the detailed treatment timeline, see the treatment process guide.
Approval is attached to a product and indication—not merely a target
The meaningful regulatory record is: Product × disease/subtype × age group × prior-treatment requirements × jurisdiction × date. A product's approval in two jurisdictions does not establish that every indication is identical.
| Status | Meaning | Access route |
|---|---|---|
| Approved product use | Authorized by a regulator (FDA, EMA, NMPA, etc.) for a defined disease, age group and line of therapy. | Commercial product through a licensed hospital. |
| Clinical trial | Under active evaluation in a registered study to determine safety and efficacy. | Enrollment through the trial's principal investigator. |
| Exceptional or compassionate access | Not approved in that jurisdiction; access limited to specific legal mechanisms and required authorisations. | Hospital-led program, eligibility decided case by case under the applicable framework. |
Do not assume approval in one country means availability in another. This single point causes most misunderstandings between patients and hospitals.
Worked example: Breyanzi (lisocabtagene maraleucel)
Breyanzi is a CD19-directed autologous CAR-T. The FDA and EMA indications are not identical. This is an example of regulatory differences, not a complete prescribing summary.
| Jurisdiction | Selected information from the source reviewed |
|---|---|
| United States — FDA | The FDA product page includes defined uses in LBCL, CLL/SLL, FL, MCL and MZL. The CLL/SLL indication is under accelerated approval. The label states Breyanzi is not indicated for primary CNS lymphoma. [citation:1] |
| European Union — EMA | The EMA product information lists defined lymphoma uses, including DLBCL, HGBCL, PMBCL and FL3B. CLL/SLL is not listed in the therapeutic indications reviewed here. [citation:2] |
European centralised marketing authorisation is issued by the European Commission following EMA assessment; "EMA approval" is convenient shorthand, not the complete description of the legal decision. Read the current product information for the full indication and restrictions.
Molecular targets: useful classification, not an eligibility result
The choice of target depends on the cancer type and the tumor's antigen expression. A target name alone does not tell you whether a product is approved for a specific disease.
CD19
Used by several approved autologous products for defined B-cell malignancies.
BCMA
Used by approved products for selected multiple-myeloma settings.
Claudin18.2
Has a specific Chinese approval for a defined gastric/GEJ indication; other cancer settings or products may remain investigational.
GPC3
Active research includes early clinical studies in HCC.
CD22 / dual-target
Research-stage approaches for B-cell malignancies.
Do not interpret target expression as a complete suitability test. Ask how expression, prior treatment and the product's requirements are assessed in the relevant disease.
Approved CAR-T products: a reference, not a prescribing summary
The products below are approved by at least one major regulator. Jurisdiction-specific approvals, indications and restrictions differ. The product page on each regulator's site is authoritative.
| Product | Target | FDA-approved indications (summary) | EMA-approved indications (summary) |
|---|---|---|---|
| Kymriah (tisagenlecleucel) | CD19 | B-ALL, DLBCL, FL | B-ALL, DLBCL, FL |
| Yescarta (axicabtagene ciloleucel) | CD19 | LBCL, FL | LBCL, FL |
| Tecartus (brexucabtagene autoleucel) | CD19 | MCL, B-ALL | MCL, B-ALL |
| Breyanzi (lisocabtagene maraleucel) | CD19 | LBCL, CLL/SLL, FL, MCL, MZL | DLBCL, HGBCL, PMBCL, FL3B, FL, MCL |
| Carvykti (ciltacabtagene autoleucel) | BCMA | Multiple myeloma | Multiple myeloma |
| Abecma (idecabtagene vicleucel) | BCMA | Multiple myeloma | Multiple myeloma |
China-specific products (Carteyva/Relma-cel, Fucaso/equecabtagene autoleucel) are NMPA-approved and covered on the China page: CAR-T therapy in China →. This reference page does not duplicate their pricing, hospitals or trial details.
Risks: severity determines the level of care
CRS can involve fever, low blood pressure and low oxygen levels. Neurological toxicity can include confusion, language difficulty, tremor, reduced alertness or seizures. These events can be life-threatening. Management depends on the event, severity, product and clinical situation.
What to ask about safety
- CRS (cytokine release syndrome): fever, hypotension, hypoxia. Tocilizumab is used in CRS management under clinical protocols.
- ICANS (neurotoxicity): confusion, aphasia, seizures. Corticosteroids and neuro-critical care may be required. Tocilizumab is not a standalone treatment for isolated ICANS.
Some programmes deliver CAR-T in an outpatient setting with close review and rapid admission when required. Outpatient treatment does not mean low risk or permission to travel away from the care team. Ask the centre how symptoms are recognised outside scheduled visits, who answers urgent calls, and how hospital escalation works.
Other risks include prolonged cytopenias, B-cell aplasia with hypogammaglobulinaemia (especially with CD19-targeted products), infection, and secondary malignancies. Product information may include additional complications such as IEC-HS. Risks and frequencies should be reported for the relevant product and population—not one pooled percentage for all CAR-T.
For the full side-effect profile, see the side effects guide.
Monitoring changed—but serious risks did not disappear
In June 2025, FDA removed the REMS programmes for six listed autologous CD19/BCMA products and updated monitoring language. The communication describes monitoring for at least two weeks, including daily monitoring for at least one week, and remaining near a healthcare facility for at least two weeks. [citation:11]
These changes are not a universal discharge or travel schedule. A product label or centre may require a longer plan for the individual patient. For example, MSK's patient guide describes follow-up near the centre and a caregiver plan for approximately 28 days in its programme. That is institutional guidance, not a global minimum. [citation:5]
FDA also distinguishes 15-year manufacturer postmarketing safety follow-up from patient monitoring for secondary malignancies. "Fifteen years" should not be presented as the point when all monitoring ends. [citation:11]
Who may be considered?
Assessment depends on the product or study and can change between referral, collection and infusion. For approved commercial treatment, the responsible clinical team under the product label decides. For a clinical trial, the study team applies the protocol and enrolment process. No intermediary, platform or agency can determine eligibility.
Diagnosis and permitted setting
The disease must match an approved indication or an open trial protocol, and the tumor must express the target antigen.
Prior therapies
Most approvals require a defined number of prior lines. Trials often require failure of specific regimens.
Organ function
Cardiac, hepatic, renal and pulmonary reserve must be adequate for lymphodepletion and CRS management.
Performance status
Relevant, but this page does not create a universal ECOG exclusion threshold. The exact criteria depend on the product label or trial protocol.
Active infection
Uncontrolled infection is usually an exclusion until treated.
Neurological history
A CNS restriction must be read precisely. For example, Breyanzi's US label excludes primary CNS lymphoma from its indication; this does not mean any previous neurological problem rules out all CAR-T. [citation:1]
For a deeper explanation, see the eligibility guide.
What if collection does not lead to infusion?
Successful collection is not a guarantee of receiving the product. Manufacturing, release requirements or a change in the patient's health can affect whether and when treatment proceeds.
Before committing, ask:
- What happens if the product cannot be released?
- Whether a repeat collection could be considered?
- How disease control is managed during delay?
- What costs or deposits apply if infusion does not occur?
- Who explains alternative care?
CancerCareE does not predict the likelihood of reaching infusion for an individual.
If there is no response or the disease returns
There is no universal "next CAR-T step". Reassessment may consider the disease, prior product, timing and pattern of relapse, remaining treatment options and the patient's condition. Further testing, another approved therapy, a trial, transplant or another cellular approach may be relevant in selected settings. None should be presented as an automatic sequence.
Supportive and palliative care need not wait until every anticancer option has ended. The care team should explain symptom support and the goals of any further treatment alongside the treatment discussion.
Clinical trials as an access pathway
A trial is not the same as an approved treatment. Trials evaluate investigational products, new targets, or new treatment settings. Enrollment is decided by the trial's principal investigator, based on protocol criteria, not by patient preference.
CancerCareE does not manage clinical trial enrollment. Trial participation decisions are made by the principal investigator. For the general mechanism of trial matching, see the clinical trials guide. To search the registry directly: ClinicalTrials.gov.
Treatment destinations
This reference page does not publish country-specific pricing, hospital lists, or eligibility rules. Those are on each destination's CAR-T page, and each is written independently.
For the cross-country cost comparison, see CAR-T cost comparison.
Questions to ask a treating CAR-T center
These questions are not a script. They are the ones that most often separate a center that can manage CAR-T safely from one that cannot.
- What is the exact product and proposed indication, and is it approved or investigational in this country?
- Is this approved use, a trial, or another documented route?
- Which parts of eligibility remain undecided?
- What are the collection, manufacturing and bridging plans?
- What could prevent infusion?
- Is treatment inpatient or outpatient, and how does urgent escalation work?
- What caregiver and proximity requirements apply?
- Which late effects require follow-up?
- How and when will response be assessed?
- What happens clinically and financially if the plan changes?
A note on the field's origins
The first evidence that CAR-modified human T cells could target cancer cells came in 1993, when Patrick Hwu and colleagues at the National Cancer Institute demonstrated that engineered T cells could target ovarian cancer cells. Two years later, the same team showed that these cells could fight tumors in living mice. This work laid a foundation for the CAR-T therapies approved today. [citation:16][citation:26]
Hwu, now president and CEO of Moffitt Cancer Center, was inducted into the Florida Inventors Hall of Fame in 2026 for his contributions to tumor immunology, including his role in the early development of gene-modified T cells. [citation:26]
"When I left MD Anderson, I did not leave my laboratory. My team and I started examining the use of CAR-T therapy for some of the more common solid tumors."
— Patrick Hwu, MD, in a 2024 profile published in Cancer [citation:16]Frequently asked questions
Is all CAR-T made from the patient's own cells?
This page primarily describes autologous products. Other cell-source approaches exist in research; the exact product and legal status must be checked. Do not apply the autologous manufacturing pathway to every experimental CAR-T.
Does CAR-T always require intensive care?
No. Some patients need intensive care for serious complications; others are monitored and treated without an ICU admission. The centre must have an appropriate escalation plan. Outpatient treatment does not mean low risk or permission to travel away from the care team.
Are approved indications the same in the US and EU?
Not necessarily. Breyanzi is one example where the current indications reviewed differ: the FDA label includes CLL/SLL under accelerated approval, while the EMA product information reviewed here does not list CLL/SLL among its therapeutic indications. [citation:1][citation:2]
Is all solid-tumour CAR-T investigational?
No longer as a universal statement across every jurisdiction. NMPA approved a CLDN18.2-directed product in June 2026 for a defined gastric/GEJ indication after at least two prior lines. That approval does not extend automatically to pancreatic cancer, HCC, other solid tumours, another CAR construct or another country. [citation:18]
Does long-term follow-up stop after 15 years?
Do not assume so. Fifteen-year postmarketing studies and lifelong monitoring for secondary malignancies are different requirements. The Breyanzi label instructs lifelong monitoring for secondary malignancies. [citation:6][citation:11]
Can CancerCareE determine whether I have a CAR-T pathway?
No. We explain public evidence and access information; we do not review records or determine individual eligibility.
Sources
- U.S. Food and Drug Administration — BREYANZI product page. fda.gov
- European Medicines Agency — Breyanzi: EPAR medicine overview. ema.europa.eu
- National Medical Products Administration (NMPA), China — 国家药监局批准舒瑞基奥仑赛注射液上市 (2026-06-22). nmpa.gov.cn
- CARsgen — Satri-cel NMPA approval announcement (2026-06-22). carsgen.com
- Memorial Sloan Kettering Cancer Center — CAR T Cell Therapy: A Guide for Adult Patients & Caregivers. mskcc.org
- U.S. Food and Drug Administration — BREYANZI prescribing information (March 2026 review). fda.gov
- U.S. Food and Drug Administration — FDA Eliminates REMS for Autologous CAR T cell Immunotherapies (June 26, 2025). fda.gov
- National Cancer Institute — CAR T Cells: Engineering Immune Cells to Treat Cancer. cancer.gov
- National Cancer Institute — Steps to Find a Clinical Trial. cancer.gov
- American Society for Transplantation and Cellular Therapy (ASTCT) — consensus grading for CRS and ICANS. astct.org
- U.S. Food and Drug Administration — FDA Safety Communication: REMS elimination and labeling updates (June 26, 2025). fda.gov
- National Comprehensive Cancer Network (NCCN) — clinical practice guidelines in oncology. nccn.org
- European Society for Blood and Marrow Transplantation (EBMT) — CAR-T patient management guidance. ebmt.org
- Golinelli G, et al. Anti-GD2 CAR T cells efficiently target Ewing's sarcoma. Cell Death & Disease. 2026. nature.com
- Moffitt Cancer Center — Dr. Patrick Hwu Inducted Into Florida Inventors Hall of Fame (2026). moffitt.org
- CancerScope — First person profile: Patrick Hwu, MD. Cancer. 2024. wiley.com
Verify the product, pathway and care plan
Print the checklist and use it with the treating team. It does not recommend a product, centre or destination.
Print the CAR-T verification checklist →